Tag:

Valeant

Latest Headlines

Latest Headlines

FDA slaps Valeant with a warning letter. Will Allergan slap it, too?

Tuesday, Valeant Pharmaceuticals said the FDA had served up a warning letter about its Sculptra Aesthetic manufacturing, citing problems it observed during a June 2014 inspection. The missteps from manufacturing standards might just fuel the fire from hostile buyout target Allergan.

Valeant hit with FDA warning letter for CMO oversight shortcomings

Valeant Pharmaceuticals has grown quickly over the past few years as it has pursued, bought and divested pharmaceutical assets. But somewhere along the way oversight of a supplier slipped. The FDA spotted the problems during a recent visit to Valeant's U.S. headquarters, leading to the posting of a warning letter.

UPDATED: Allergan's next tug-of-war move: Attack Valeant's rosy Q3 forecast

Allergan may or may not bow to requests from some of its largest shareholders to wait on M&A until after December's special meeting. But in the meantime, it's continuing its barrage on predator Valeant's sales model, which it says will yield a tough Q4.

Allergan buy Salix? Not so fast, say investors intent on Valeant vote

Valeant Pharmaceuticals isn't the only one who thinks Allergan should hold off on dealmaking till shareholders say their piece at a December special meeting. Three top-15 Allergan shareholders are urging the Botox maker to delay until investors weigh in on Valeant's hostile bid.

Valeant adds activist shareholder Ubben to board as Allergan takeover bid heats up

In yet another sign that it's not about to abandon its hostile bid to buy Allergan, Valeant has named activist investor Jeffrey Ubben to its board. Ubben is chief executive officer of ValueAct Capital Management, Valeant's second-largest shareholder and a new supporter of the Allergan deal.

Valeant talks up the billion-dollar potential of its Phase III eye drug

Valeant Pharmaceuticals is famous for its aversion to pharmaceutical R&D, but the serial acquirer makes an exception when it sees blockbuster promise in a late-stage asset. And that's the case for the glaucoma treatment Vesneo, which met its goals in pivotal trials and, according to the company, has blockbuster potential.

Ackman threatens Allergan with lawsuit if Salix deal is sealed

The ongoing attempt by Allergan to thwart a Valeant takeover by bulking up with an acquisition of its own has officially turned nasty. On Tuesday, activist investor William Ackman of Pershing Square Capital Management sent a letter to Allergan threatening to sue the company if it goes ahead with its plan to buy Salix Pharmaceuticals--a deal that reportedly could exceed $10 billion.

Allergan, Valeant agree on meeting date. Now, the fight for shareholder votes

After months of battling between Allergan and its pursuers, Valeant and Pershing Square Capital Management, the two sides have reached a truce--at least when it comes to an upcoming shareholder meeting.

Allergan special meeting could happen with or without Ackman's stake

Allergan had hoped that a lawsuit could potentially prevent Valeant's takeover partner--Bill Ackman, whose Pershing Square Capital Management is Allergan's leading shareholder--from contributing to the 25% investor support threshold needed to call a special meeting. But now, Reuters ' sources say, Team Valeant has rallied support from shareholders holding 35% of the company.

Wake up, Ackman tells Allergan's board. He has a 50%-60% chance of replacing you

In a Tuesday letter, activist investor Bill Ackman urged Allergan's directors to listen to what Valeant's putting on the table and assured them that they could still "rescue" their reputations by taking over leadership from CEO David Pyott, Reuters reports.